摘要
许多潜在的治疗神经系统疾病的药物因为血脑屏障而不能够达到足够的浓度治疗。一方面,药物到脑部的直接给药与系统性药物传输相比具有一个更大的治疗毒性比例。治疗药物由鼻内到脑部的递质的应用以一种非入侵性的行为避开了血脑屏障。在这方面,纳米药物载体与等价的药物溶液配方相比,其能够提高进入到中枢神经系统的药物浓度。神经病学上的条件已经在动物模型上进行了研究,表明从鼻到脑部投递的纳米治疗递质主要对以下病征有益,包括疼痛、癫痫、神经退行性疾病和传染性疾病。通过鼻到脑部路线的药物递质大有研究前途。在通过药物传输系统例如聚合纳米粒子和与大分子量生物制剂由鼻内传递到中枢神经系统有关的临床前研究的基础上,对鼻粘膜的毒性、纳米粒子运输到脑部、这些给药系统的临床转化、只对大脑特定区域给药和吸收剂量的可变性仍然是当前需要被考虑的研究热点。
关键词: 血脑屏障,纳米医学,纳米粒子,神经障碍,鼻子到脑部,嗅觉神经
Current Medicinal Chemistry
Title:Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders
Volume: 21 Issue: 37
Author(s): Wei-Yi Ong, Suku-Maran Shalini and Luca Costantino
Affiliation:
关键词: 血脑屏障,纳米医学,纳米粒子,神经障碍,鼻子到脑部,嗅觉神经
摘要: Many potential drugs for the treatment of neurological diseases are unable to reach the brain in sufficient enough concentrations to be therapeutic because of the blood brain barrier. On the other hand, direct delivery of drugs to the brain provides the possibility of a greater therapeutic-toxic ratio than with systemic drug delivery. The use of intranasal delivery of therapeutic agents to the brain provides a means of bypassing the blood brain barrier in a non-invasive manner. In this respect, nanosized drug carriers were shown to enhance the delivery of drugs to CNS compared to equivalent drug solution formulations. Neurological conditions that have been studied in animal models that could benefit from nose-to-brain delivery of nanotherapeutics include pain, epilepsy, neurodegenerative disease and infectious diseases. The delivery of drugs to the brain via the nose-to-brain route holds great promise, on the basis of preclinical research by means of drug delivery systems such as polymeric nanoparticles and clinical data related to intranasal delivery to CNS of large molecular weight biologics administered in solution, but safety issues about toxicity on nasal mucosa, Np transport into the brain, delivery only to specific brain regions and variability in the adsorbed dose still represent research topics that need to be considered, with a view of clinical translation of these delivery systems.
Export Options
About this article
Cite this article as:
Ong Wei-Yi, Shalini Suku-Maran and Costantino Luca, Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders, Current Medicinal Chemistry 2014; 21 (37) . https://dx.doi.org/10.2174/0929867321666140716103130
DOI https://dx.doi.org/10.2174/0929867321666140716103130 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gut Microbiota as a Link between Modern Lifestyle and Alzheimer’s Disease
Current Aging Science Genetics of Bladder-Exstrophy-Epispadias Complex (BEEC): Systematic Elucidation of Mendelian and Multifactorial Phenotypes
Current Genomics Gliomas: Current Issues in Diagnosis and Treatment
Current Medical Imaging Recent Advances and Patents on Nanoscale Systems and Triggerable Drug Delivery in Medical Devices
Recent Patents on Biomedical Engineering (Discontinued) Adult Neurogenesis in the Hypothalamus: Evidence, Functions and Implications
CNS & Neurological Disorders - Drug Targets Imaging of P-glycoprotein Function and Expression to Elucidate Mechanisms of Pharmacoresistance in Epilepsy
Current Topics in Medicinal Chemistry Activity-Dependent Release of Adenosine: A Critical Re-Evaluation of Mechanism
Current Neuropharmacology Meningitis Due to Cryptococcus neoformans: Treatment with Posaconazole
Current HIV Research Pharmacology of Recombinant Low-Voltage Activated Calcium Channels
Current Drug Targets - CNS & Neurological Disorders Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions
Recent Patents on Anti-Cancer Drug Discovery Synthesis, Antifungal Activity and Carbonic Anhydrase Inhibitory Properties of Cu (II) Bis (3, 4 Dimethoxybenzoate) Bis (Nicotinamide) Dihydrate
Current Enzyme Inhibition Anticonvulsant Action and Long-term Effects of Gabapentin
Current Neuropharmacology Pediatric Epilepsy Surgery: Neuropsychological and Psychosocial Outcomes
Current Pediatric Reviews Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Commentary: Participation of Sox-1 Expression and Signaling of β-Catenin in the Pathophysiology of Generalized Seizures in Cerebellum of Rat
CNS & Neurological Disorders - Drug Targets Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Convulsions with Gastroenteritis: Reflections on some Cases and Tentative Diagnostic Score
Current Pediatric Reviews Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Is Going for Cure in CML Targeting Aberrant Glycogen Synthase Kinase 3β?
Current Drug Targets